Skip to main content

Table 2 Comparison of the therapeutic effects of DBS in patients carrying VPD35 p.D620N mutation and sporadic PD

From: Identification of VPS35 p.D620N mutation-related Parkinson’s disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review

Reference VPD35 p.D620N mutation carriers Age of onset (mean ± SD, years) Age at receiving DBS (mean ± SD, years) DBS stimulation details that gained the best clinical response LEDD before DBS (mg) LEDD one year after DBS (mg) Improvement of UPDRS motor scores one year after DBS in “OFF” medications LEDD five to eight years after DBS (mg)
Fleury V et al., 2013 [14] +
(patient 1)
49 60 Monopolar stimulation of two most proximal contacts (3-) at 2.2 V in the right STN and 2.4 V in the left STN, with a frequency of 130 Hz and pulse duration of 60 ms. 1540 400 76% 550 (eight years after DBS)
  +
(patient 2)
45 55 Monopolar stimulation of the 3rd and 4th distal contact (2–3-) in the right STN at 3.3 V and 3.0 V in the left STN, with a frequency of 180 Hz and pulse duration of 90 ms. 1276.5 300 36% N.A.
Current study +
(index patient)
42 55 Monopolar stimulation of the two dorsal contacts (6−/2-) at 4.4 V in the right STN and 3.2 V in the left STN, with a frequency of 160 Hz and pulse duration of 90 ms in the right STN and 60 ms in the left STN 1435 1000 37% 1160 (five years after DBS)
Aviles-Olmos I et al., 2014 [16] -
41 sporadic PD patients
43.3 ± 9.8 56.2 ± 8.4 Monopolar stimulation 1471 ± 515 949 ± 572 45.5 ± 12.8% 668 ± 359 (five years after DBS)
  1. DBS deep brain stimulation, STN subthalamic nucleus, LEDD levodopa equivalent dose, SD standard deviation, N.A. not available